-
Innovation Ranking
NewInnovation Ranking – Sesen Bio Inc
Carisma Therapeutics Inc (Carisma Therapeutics), formerly Sesen Bio Inc, is a late-stage clinical company that develops targeted fusion protein therapeutics (TFPTs) for the treatment of patients with cancer. The company’s TFPTs genetically combines targeting antibody fragments with cytotoxic protein payloads. Carisma Therapeutics' product pipeline includes Vicinium (VB4-845) also known as oportuzumab monatox, which is used for the treatment of high-grade non-muscle invasive bladder cancer(NMIBC). The company operates in the US, the UK, and Canada. Carisma Therapeutics is headquartered in Cambridge,...
-
Company Profile
Carisma Therapeutics Inc – Company Profile
Carisma Therapeutics Inc (Carisma Therapeutics), formerly Sesen Bio Inc, is a late-stage clinical company that develops targeted fusion protein therapeutics (TFPTs) for the treatment of patients with cancer. The company’s TFPTs genetically combines targeting antibody fragments with cytotoxic protein payloads. Carisma Therapeutics' product pipeline includes Vicinium (VB4-845) also known as oportuzumab monatox, which is used for the treatment of high-grade non-muscle invasive bladder cancer(NMIBC). The company operates in the US, the UK, and Canada. Carisma Therapeutics is headquartered in Cambridge,...
Add to Basket -
Product Insights
Bladder Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Bladder cancer occurs in tissues of the urinary bladder whose symptoms include blood or blood clots in the urine, frequent urination, lower back pain on one side of the body, and burning during urination. Risk factors for bladder cancer include smoking, exposure to substances such as rubber, certain dyes and textiles, paint, and hairdressing supplies, diet rich in fried meats and fat, old age, sex and color, and certain parasitic infections. The Bladder Cancer pipeline market research report provides comprehensive...
-
Product Insights
Net Present Value Model: Vicinium
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Vicinium Drug Details Oportuzumab monatox (Vicinium,...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – EBI-031
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry EBI-031 Drug Details RG-6179 (EBI-031) is under development for the treatment of diabetic macular...
-
Sector Analysis
United States In Vitro Diagnostics Market Outlook to 2025 – Cardiac Disease, Clinical Chemistry, Hematological Disorders and Others
GlobalData’s “United States In Vitro Diagnostics Market Outlook to 2025” is a comprehensive databook report, covering key market data on the United States In Vitro Diagnostics market. The databook report provides value (USD), volume (units) and average prices (USD) within market segments – Cardiac Disease, Clinical Chemistry, Hematological Disorders, Hormonal Disorders, Infectious Disease, IVD Analyzers and Reagents, Metabolic Disorder, Oncology and Women's Health. The United States In Vitro Diagnostics Market report provides key information and data on: • Annualized market...